Neoadjuvant Sintilimab Plus Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

Huilai Lv, Yang Tian, Jiachen Li, Chao Huang, Bokang Sun, Chunyue Gai, Zhenhua Li, Ziqiang Tian, Huilai Lv, Yang Tian, Jiachen Li, Chao Huang, Bokang Sun, Chunyue Gai, Zhenhua Li, Ziqiang Tian

Abstract

Background: Neoadjuvant chemotherapy (nCT) and chemoradiotherapy (nCRT) are the standard treatments in patients with resectable locally advanced esophageal squamous cell carcinoma (ESCC). Adding PD-1 inhibitor to the chemotherapy has shown significant clinical benefits in first-line treatment of advanced ESCC. This study evaluated the efficacy and safety of neoadjuvant sintilimab plus chemotherapy in patients with resectable locally advanced ESCC.

Methods: The clinical data of 96 patients with resectable locally advanced ESCC, treated with sintilimab plus chemotherapy followed by esophagectomy, were reviewed. The pathologic complete response (pCR) rate, major pathological response (MPR) rate, R0 resection rate, tumor downstaging, survival, and safety were retrospectively analyzed.

Results: Patients were between the ages of 43 and 78 years (interquartile range [IQR], 60-69 years). Forty (41.7%) were diagnosed with stage II ESCC, 52 (54.2%) with stage III, and 4 (4.2%) with stage IVA. Sixty-seven (69.8%) were male, and 84 (87.5%) patients had an ECOG PS of ≤1. Forty-eight (50.0%) patients received 3-4 cycles of the neoadjuvant treatment. Twenty-nine (30.2%) patients obtained pCR, and MPR was achieved in 60 (62.5%) patients. The R0 resection rate was 99%. Eighty (83.3%) patients achieved clinical downstaging, and 71 (74.0%) achieved pathological downstaging. The median follow-up was 8.9 months, and 1-year DFS rate was 95.2% (95% CI, 88.8%-100%). Grade 3-4 TRAEs occurred in 12 (12.5%) patients, and the incidence of grade 3-4 surgical complications was 2.1%. No deaths were reported.

Conclusion: These real-world data revealed that neoadjuvant sintilimab plus chemotherapy could provide encouraging pCR with good tolerability for resectable locally advanced ESCC, and this regimen warrants further exploration in prospective clinical studies.

Keywords: combination therapy; esophageal squamous cell carcinoma; immune checkpoint inhibitors; pathologic complete response; sintilimab.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2022 Lv, Tian, Li, Huang, Sun, Gai, Li and Tian.

Figures

Figure 1
Figure 1
Kaplan–Meier estimates of DFS.

References

    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin (2021) 71(3):209–49. doi: 10.3322/caac.21660
    1. Cao W, Chen HD, Yu YW, Li N, Chen WQ. Changing Profiles of Cancer Burden Worldwide and in China: A Secondary Analysis of the Global Cancer Statistics 2020. Chin Med J (Engl) (2021) 134(7):783–91. doi: 10.1097/CM9.0000000000001474
    1. He Y, Li D, Shan B, Liang D, Shi J, Chen W, et al. . Incidence and Mortality of Esophagus Cancer in China, 2008-2012. Chin J Cancer Res (2019) 31(3):426–34. doi: 10.21147/j.issn.1000-9604.2019.03.04
    1. Lin Y, Totsuka Y, He Y, Kikuchi S, Qiao Y, Ueda J, et al. . Epidemiology of Esophageal Cancer in Japan and China. J Epidemiol (2013) 23(4):233–42. doi: 10.2188/jea.je20120162
    1. Guo X, Mao T, Gu Z, Ji C, Fang W. Clinical Study on Postoperative Recurrence in Patients With Pn1 Esophageal Squamous Cell Carcinoma. Thorac Cancer (2015) 6(2):146–50. doi: 10.1111/1759-7714.12155
    1. Ninomiya I, Okamoto K, Tsukada T, Kinoshita J, Oyama K, Fushida S, et al. . Recurrence Patterns and Risk Factors Following Thoracoscopic Esophagectomy With Radical Lymph Node Dissection for Thoracic Esophageal Squamous Cell Carcinoma. Mol Clin Oncol (2016) 4(2):278–84. doi: 10.3892/mco.2015.688
    1. Lindenmann J, Fediuk M, Fink-Neuboeck N, Porubsky C, Pichler M, Brcic L, et al. . Hazard Curves for Tumor Recurrence and Tumor-Related Death Following Esophagectomy for Esophageal Cancer. Cancers (Basel) (2020) 12(8):2066. doi: 10.3390/cancers12082066
    1. National Comprehensive Cancer Network . NCCN Clinical Practice Guidelines in Oncology: Esophageal and Esophagogastric Junction Cancers (2022). Available at: .
    1. Chinese Society of Clinical Oncology . CSCO Clinical Guidelines for the Diagnosis and Treatment of Esophageal Cancer (2021). Available at: .
    1. Allum WH, Stenning SP, Bancewicz J, Clark PI, Langley RE. Long-Term Results of a Randomized Trial of Surgery With or Without Preoperative Chemotherapy in Esophageal Cancer. J Clin Oncol (2009) 27(30):5062–7. doi: 10.1200/JCO.2009.22.2083
    1. Medical Research Council Oesophageal Cancer Working Group . Surgical Resection With or Without Preoperative Chemotherapy in Oesophageal Cancer: A Randomised Controlled Trial. Lancet (2002) 359(9319):1727–33. doi: 10.1016/S0140-6736(02)08651-8
    1. van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, et al. . Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer. N Engl J Med (2012) 366(22):2074–84. doi: 10.1056/NEJMoa1112088
    1. Eyck BM, van Lanschot JJB, Hulshof MCCM, van der Wilk BJ, Shapiro J, van Hagen P, et al. . Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial. J Clin Oncol (2021) 39(18):1995–2004. doi: 10.1200/JCO.20.03614
    1. Ando N, Kato H, Igaki H, Shinoda M, Ozawa S, Shimizu H, et al. . A Randomized Trial Comparing Postoperative Adjuvant Chemotherapy With Cisplatin and 5-Fluorouracil Versus Preoperative Chemotherapy for Localized Advanced Squamous Cell Carcinoma of the Thoracic Esophagus (JCOG9907). Ann Surg Oncol (2012) 19(1):68–74. doi: 10.1245/s10434-011-2049-9
    1. Yang H, Liu H, Chen Y, Zhu C, Fang W, Yu Z, et al. . Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial. J Clin Oncol (2018) 36(27):2796–803. doi: 10.1200/JCO.2018.79.1483
    1. Yang H, Liu H, Chen Y, Zhu C, Fang W, Yu Z, et al. . Long-Term Efficacy of Neoadjuvant Chemoradiotherapy Plus Surgery for the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma: The NEOCRTEC5010 Randomized Clinical Trial. JAMA Surg (2021) 156(8):721–9. doi: 10.1001/jamasurg.2021.2373
    1. Sakai H, Kokura S, Ishikawa T, Tsuchiya R, Okajima M, Matsuyama T, et al. . Effects of Anticancer Agents on Cell Viability, Proliferative Activity and Cytokine Production of Peripheral Blood Mononuclear Cells. J Clin Biochem Nutr (2013) 52(1):64–71. doi: 10.3164/jcbn.12-60
    1. Pol J, Vacchelli E, Aranda F, Castoldi F, Eggermont A, Cremer I, et al. . Trial Watch: Immunogenic Cell Death Inducers for Anticancer Chemotherapy. Oncoimmunology (2015) 4(4):e1008866. doi: 10.1080/2162402X.2015.1008866
    1. Heinhuis KM, Ros W, Kok M, Steeghs N, Beijnen JH, Schellens JHM. Enhancing Antitumor Response by Combining Immune Checkpoint Inhibitors With Chemotherapy in Solid Tumors. Ann Oncol (2019) 30(2):219–35. doi: 10.1093/annonc/mdy551
    1. Sun JM, Shen L, Shah MA, Enzinger P, Adenis A, Doi T, et al. . Pembrolizumab Plus Chemotherapy Versus Chemotherapy Alone for First-Line Treatment of Advanced Oesophageal Cancer (KEYNOTE-590): A Randomised, Placebo-Controlled, Phase 3 Study. Lancet (2021) 398(10302):759–71. doi: 10.1016/S0140-6736(21)01234-4
    1. Shen L, Lu Z, Wang J, Shu Y, Kong L, Yang L, et al. . LBA52 Sintilimab Plus Chemotherapy Versus Chemotherapy as First-Line Therapy in Patients With Advanced or Metastatic Esophageal Squamous Cell Cancer: First Results of the Phase III ORIENT-15 Study. Ann Oncol (2021) 32(suppl_5):S1283–346. doi: 10.1016/annonc/annonc741
    1. Li Z, Sun Y, Ye F, Ma D, Yin X, Zhuang W, et al. . First-Line Pembrolizumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Esophageal Cancer: Chinese Subgroup Analysis of KEYNOTE-590. J Clin Oncol 39 (2021) suppl 15:abstr 4049. doi: 10.1200/JCO.2021.39.15_suppl.4049
    1. Chau I, Doki Y, Ajani JA, Xu JM, Wyrwicz L, Motoyama S, et al. . Nivolumab (NIVO) Plus Ipilimumab (IPI) or NIVO Plus Chemotherapy (Chemo) Versus Chemo as First-Line (1L) Treatment for Advanced Esophageal Squamous Cell Carcinoma (ESCC): First Results of the CheckMate 648 Study. J Clin Oncol 39 (2021) suppl 15:abstr LBA4001. doi: 10.1200/JCO.2021.39.15_suppl.LBA4001
    1. Luo H, Lu J, Bai Y, Mao T, Wang J, Fan Q, et al. . Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial. JAMA (2021) 326(10):916–25. doi: 10.1001/jama.2021.12836
    1. Xu R, Wang F, Cui C, Yao J, Zhang Y, Wang G, et al. . JUPITER-06: A Randomized, Double-Blind, Phase III Study of Toripalimab Versus Placebo in Combination With First-Line Chemotherapy for Treatment Naive Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC). Ann Oncol (2021) 32(suppl_5):S1040–75. doi: 10.1016/annonc/annonc708
    1. Xing W, Zhao L, Zheng Y, Liu B, Liu X, Li T, et al. . The Sequence of Chemotherapy and Toripalimab Might Influence the Efficacy of Neoadjuvant Chemoimmunotherapy in Locally Advanced Esophageal Squamous Cell Cancer-A Phase II Study. Front Immunol (2021) 12:772450. doi: 10.3389/fimmu.2021.772450
    1. Yang P, Zhou X, Yang X, Wang Y, Sun T, Feng S, et al. . Neoadjuvant Camrelizumab Plus Chemotherapy in Treating Locally Advanced Esophageal Squamous Cell Carcinoma Patients: A Pilot Study. World J Surg Oncol (2021) 19(1):333. doi: 10.1186/s12957-021-02446-5
    1. Shen D, Chen Q, Wu J, Li J, Tao K, Jiang Y. The Safety and Efficacy of Neoadjuvant PD-1 Inhibitor With Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma. J Gastrointest Oncol (2021) 12(1):1–10. doi: 10.21037/jgo-20-599
    1. Zhang Z, Hong ZN, Xie S, Lin W, Lin Y, Zhu J, et al. . Neoadjuvant Sintilimab Plus Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Single-Arm, Single-Center, Phase 2 Trial (ESONICT-1). Ann Transl Med (2021) 9(21):1623. doi: 10.21037/atm-21-5381
    1. Li Z, Liu J, Zhang M, Shao J, Yang Y, Li H, et al. . A Phase II Study of Neoadjuvant Immunotherapy Combined With Chemotherapy (Camrelizumab Plus Albumin Paclitaxel and Carboplatin) in Resectable Thoracic Esophageal Squamous Cell Cancer (NICE Study): Interim Results. J Clin Oncol 39 (2021) suppl 15:abstr 4060. doi: 10.1200/JCO.2021.39.15_suppl.4060
    1. Li J, Liu J, Li Z, Cui F, Zeng Y, Liang W, et al. . Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy for Resectable, Locally Advanced Esophageal Squamous Cell Carcinoma (NIC-ESCC2019): A Multicenter, Open-Label, Single-Arm, Phase 2 Study. J Clin Oncol 39 (2021) suppl 15:abstr 4028. doi: 10.1200/JCO.2021.39.15_suppl.4028
    1. Shang X, Zhang C, Zhao G, Zhang W, Liu L, Duan X, et al. . Safety and Efficacy of Pembrolizumab Combined With Paclitaxel and Cisplatin as a Neoadjuvant Treatment for Locally Advanced Resectable (Stage III) Esophageal Squamous Cell Carcinoma (Keystone-001): Interim Analysis of a Prospective, Single-Arm, Single-Center, Phase II Trial. Ann Oncol (2021) 32(suppl_7):S1428–57. doi: 10.1016/annonc/annonc787
    1. Ma J, Zhang J, Yang Y, Zheng D, Wang X, Liang H, et al. . Camrelizumab Combined With Paclitaxel and Nedaplatin as Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma (ESPRIT): A Phase II, Single-Arm, Exploratory Research. Ann Oncol (2021) 32(suppl_7):S1398–427. doi: 10.1016/annonc/annonc786
    1. Yan X, Zhao J, Lei J, Duan H, Ni Y, Zhou Y, et al. . Tislelizumab Combined With Chemotherapy as Neoadjuvant Therapy for Surgically Resectable Esophageal Cancer (TD-NICE): A Single Arm, Phase II Study. Ann Oncol (2021) 32(suppl_7):S1428–57. doi: 10.1016/annonc/annonc787
    1. Gu Y, Chen X, Wang D, Ding M, Xue L, Zhen F, et al. . A Study of Neoadjuvant Sintilimab Combined With Triplet Chemotherapy of Lipo-Paclitaxel, Cisplatin, and S-1 for Resectable Esophageal Squamous Cell Carcinoma (ESCC). Ann Oncol (2020) 31(suppl_6):S1287–318. doi: 10.1016/annonc/annonc356
    1. Wang H, Tang H, Fang Y, Tan L, Yin J, Shen Y, et al. . Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial. JAMA Surg (2021) 156(5):444–51. doi: 10.1001/jamasurg.2021.0133
    1. Tang H, Zheng H, Tan L, Shen Y, Wang H, Lin M, et al. . Neoadjuvant Chemoradiotherapy Followed by Minimally Invasive Esophagectomy: Is It a Superior Approach for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma? J Thorac Dis (2018) 10(2):963–72. doi: 10.21037/jtd.2017.12.108
    1. Zhang G, Zhang C, Sun N, Xue L, Yang Z, Fang L, et al. . Neoadjuvant Chemoradiotherapy Versus Neoadjuvant Chemotherapy for the Treatment of Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Study From the National Cancer Center in China. J Cancer Res Clin Oncol (2021) 148(4):943–54. doi: 10.1007/s00432-021-03659-7
    1. Kurogochi T, Honda M, Takahashi K, Okamura A, Imamura Y, Yamashita K, et al. . Clinical Features and Risk Factors for Early Recurrence After Esophagectomy Following Neoadjuvant Chemotherapy for Esophageal Cancer. Surg Today (2021) 52(4):660–67. doi: 10.1007/s00595-021-02397-0
    1. Pennathur A, Luketich JD, Landreneau RJ, Ward J, Christie NA, Gibson MK, et al. . Long-Term Results of a Phase II Trial of Neoadjuvant Chemotherapy Followed by Esophagectomy for Locally Advanced Esophageal Neoplasm. Ann Thorac Surg (2008) 85(6):1930–6; discussion 1936-7. doi: 10.1016/j.athoracsur.2008.01.097
    1. Pasini F, de Manzoni G, Pedrazzani C, Grandinetti A, Durante E, Gabbani M, et al. . High Pathological Response Rate in Locally Advanced Esophageal Cancer After Neoadjuvant Combined Modality Therapy: Dose Finding of a Weekly Chemotherapy Schedule With Protracted Venous Infusion of 5-Fluorouracil and Dose Escalation of Cisplatin, Docetaxel and Concurrent Radiotherapy. Ann Oncol (2005) 16(7):1133–9. doi: 10.1093/annonc/mdi207
    1. Castoro C, Scarpa M, Cagol M, Ruol A, Cavallin F, Alfieri R, et al. . Nodal Metastasis From Locally Advanced Esophageal Cancer: How Neoadjuvant Therapy Modifies Their Frequency and Distribution. Ann Surg Oncol (2011) 18(13):3743–54. doi: 10.1245/s10434-011-1753-9
    1. Kobayashi K, Kanetaka K, Yoneda A, Kobayashi S, Maruya Y, Isagawa Y, et al. . Downstaging and Histological Effects Might Be Reliable Predictors of the Efficacy of DOC+CDDP+5-FU (DCF) as Neoadjuvant Therapy for Stage III or Borderline Resectable Esophageal Cancer: A Single Institute Experience. J Gastrointest Cancer (2021) 52(2):582–92. doi: 10.1007/s12029-020-00431-x
    1. Watanabe M, Baba Y, Yoshida N, Ishimoto T, Nagai Y, Iwatsuki M, et al. . Outcomes of Preoperative Chemotherapy With Docetaxel, Cisplatin, and 5-Fluorouracil Followed by Esophagectomy in Patients With Resectable Node-Positive Esophageal Cancer. Ann Surg Oncol (2014) 21(9):2838–44. doi: 10.1245/s10434-014-3684-8
    1. Wang W, Yi Y, Jia Y, Dong X, Zhang J, Song X, et al. . Neoadjuvant Chemotherapy With Liposomal Paclitaxel Plus Platinum for Locally Advanced Esophageal Squamous Cell Cancer: Results From a Retrospective Study. Thorac Cancer (2022) 13(6):824–31. doi: 10.1111/1759-7714.14328
    1. Korst RJ, Kansler AL, Port JL, Lee PC, Kerem Y, Altorki NK. Downstaging of T or N Predicts Long-Term Survival After Preoperative Chemotherapy and Radical Resection for Esophageal Carcinoma. Ann Thorac Surg (2006) 82(2):480–4; discussion 484-5. doi: 10.1016/j.athoracsur.2006.03.072
    1. Ribeiro A, Franceschi D, Parra J, Livingstone A, Lima M, Hamilton-Nelson K, et al. . Endoscopic Ultrasound Restaging After Neoadjuvant Chemotherapy in Esophageal Cancer. Am J Gastroenterol (2006) 101(6):1216–21. doi: 10.1111/j.1572-0241.2006.00692.x
    1. Fan Y, Jiang Y, Zhou X, Chen Q, Huang Z, Xu Y, et al. . Phase II Study of Neoadjuvant Therapy With Nab-Paclitaxel and Cisplatin Followed by Surgery in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma. Oncotarget (2016) 7(31):50624–34. doi: 10.18632/oncotarget.9562
    1. Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera-Knorrenschild J, et al. . Phase III Comparison of Preoperative Chemotherapy Compared With Chemoradiotherapy in Patients With Locally Advanced Adenocarcinoma of the Esophagogastric Junction. J Clin Oncol (2009) 27(6):851–6. doi: 10.1200/JCO.2008.17.0506
    1. Klevebro F, Alexandersson von Döbeln G, Wang N, Johnsen G, Jacobsen AB, Friesland S, et al. . A Randomized Clinical Trial of Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Cancer of the Oesophagus or Gastro-Oesophageal Junction. Ann Oncol (2016) 27(4):660–7. doi: 10.1093/annonc/mdw010
    1. Nakashima Y, Saeki H, Hu Q, Tsuda Y, Hisamatsu Y, Ando K, et al. . Neoadjuvant Chemotherapy Versus Chemoradiotherapy for Patients With Esophageal Squamous Cell Carcinoma. Anticancer Res (2018) 38(12):6809–14. doi: 10.21873/anticanres.13053
    1. Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, et al. . Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. N Engl J Med (2021) 384(13):1191–203. doi: 10.1056/NEJMoa2032125

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다